TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
Brief Summary: Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, when added to metformin in people with type 2 diabetes who are not at target blood glucose levels on metformin alone.


Options:
A: Arm Label: Sitagliptin 100 mg/100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin (MK0431), Drug: Metformin - Rescue | Arm Label: Sitagliptin 200 mg/200 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin, Drug: Metformin - Rescue | Arm Label: Placebo/Sitagliptin 100 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin - Rescue | Arm Label: Placebo/Sitagliptin 200 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin - Rescue | Intervention Type: DRUG; Name: Sitagliptin (MK0431); Assigned to Arm(s): Sitagliptin 100 mg/100 mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin 200 mg/200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin 200 mg | Intervention Type: DRUG; Name: Metformin - Rescue; Assigned to Arm(s): Placebo/Sitagliptin 100 mg, Placebo/Sitagliptin 200 mg, Sitagliptin 100 mg/100 mg, Sitagliptin 200 mg/200 mg
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
D: Arm Label: Vildagliptin 50 mg qd + pioglitazone 45 mg qd; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: pioglitazone | Arm Label: Vildagliptin 50 mg bid + pioglitazone 45 mg qd; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: pioglitazone | Arm Label: Vildagliptin placebo + pioglitazone 45 mg qd; Type: PLACEBO_COMPARATOR; Interventions: Drug: pioglitazone, Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin 50 mg bid + pioglitazone 45 mg qd, Vildagliptin 50 mg qd + pioglitazone 45 mg qd | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Vildagliptin 50 mg bid + pioglitazone 45 mg qd, Vildagliptin 50 mg qd + pioglitazone 45 mg qd, Vildagliptin placebo + pioglitazone 45 mg qd | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Vildagliptin placebo + pioglitazone 45 mg qd

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
Brief Summary: The purpose of this study is to assess the safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar.


Options:
A: Arm Label: Arm 1 Treatment A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosiglitazone | Arm Label: Arm 2 Treatment B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Arm 1 Treatment A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Arm 2 Treatment B
B: Intervention Type: DRUG; Name: Glucovance (metformin HCl/glyburide); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: or Metformin HCl alone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: or Glyburide alone.; Assigned to Arm(s): N/A
C: Arm Label: Saxagliptin 2.5 mg (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 5 mg (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 10 mg (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Placebo (D); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching Saxagliptin, Drug: Metformin | Arm Label: Open-Label Treatment Cohort (Direct Enrollees) (E); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg (A) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 10 mg (C) | Intervention Type: DRUG; Name: Placebo matching Saxagliptin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Placebo matching Metformin; Assigned to Arm(s): Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E), Placebo (D), Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B)
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
Brief Summary: The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.


Options:
A: Arm Label: Metformin,lifestyle counselling; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosiglitazone, Drug: metformin, Drug: Anti-diabetic medications | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): Metformin,lifestyle counselling | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Metformin,lifestyle counselling | Intervention Type: DRUG; Name: Anti-diabetic medications; Assigned to Arm(s): Metformin,lifestyle counselling
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Liraglutide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Liraglutide + Metformin, Metformin alone | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide + Metformin | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
Brief Summary: The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Arm Label: Sitagliptin 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Sitagliptin, Drug: Comparator: Pioglitazone, Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo, Drug: Comparator: Pioglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Comparator: Sitagliptin; Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Comparator: Pioglitazone; Assigned to Arm(s): Placebo, Sitagliptin 100 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo, Sitagliptin 100 mg
C: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Brief Summary: Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to insulin in people with type 2 diabetes who are not at target blood glucose levels on insulin alone.


Options:
A: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Brief Summary: Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to insulin in people with type 2 diabetes who are not at target blood glucose levels on insulin alone.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Arm Label: Sitagliptin 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Sitagliptin, Drug: Comparator: Pioglitazone, Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo, Drug: Comparator: Pioglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Comparator: Sitagliptin; Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Comparator: Pioglitazone; Assigned to Arm(s): Placebo, Sitagliptin 100 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo, Sitagliptin 100 mg
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vildagliptin Placebo | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Vildagliptin 50 mg qd + pioglitazone 45 mg qd; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: pioglitazone | Arm Label: Vildagliptin 50 mg bid + pioglitazone 45 mg qd; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: pioglitazone | Arm Label: Vildagliptin placebo + pioglitazone 45 mg qd; Type: PLACEBO_COMPARATOR; Interventions: Drug: pioglitazone, Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin 50 mg bid + pioglitazone 45 mg qd, Vildagliptin 50 mg qd + pioglitazone 45 mg qd | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Vildagliptin 50 mg bid + pioglitazone 45 mg qd, Vildagliptin 50 mg qd + pioglitazone 45 mg qd, Vildagliptin placebo + pioglitazone 45 mg qd | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Vildagliptin placebo + pioglitazone 45 mg qd

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Response to Cranberry of Women With Recurrent UTIs
Brief Summary: The purpose of this study is to determine the role of cranberry-containing products in preventing urinary tract infections (UTIs).


Options:
A: Arm Label: Cranberry Juice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice, Dietary Supplement: Cranberry Juice | Arm Label: Placebo cranberry juice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo cranberry juice | Intervention Type: DRUG; Name: Cranberry juice; Assigned to Arm(s): Cranberry Juice | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry Juice; Assigned to Arm(s): Cranberry Juice | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo cranberry juice; Assigned to Arm(s): Placebo cranberry juice
B: Intervention Type: DRUG; Name: Cranberries - Vaccinium macrocarpon; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Cranberry capsule; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cranberry capsules | Arm Label: Placebo capsule; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry capsules; Assigned to Arm(s): Cranberry capsule, Placebo capsule

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial
Brief Summary: Primary Outcome Measures:Incidence density of colonization with MRSA or VRE (number of new colonization events per 1000 patient days at risk) during the intervention phase. Secondary Outcome Measures:The effect of the 2 strategies on the incidence density of colonization with MRSA and VRE individually will be determined and compared descriptively. The effect of the strategies on the cumulative incidence of bacteremia caused by MRSA and VRE will be determined to assess the clinical relevance of the strategy in preventing infection. The trial will evaluate the frequency of hand hygiene and the use of gloves and gowns by healthcare workers to substantiate whether the effect of the intensive control strategy is mediated, as expected, by an increase in the use of gloves and gowns due to an increase in the number of patients cared for using Contact Precautions.


Options:
A: Arm Label: White coat group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Uniform group; Type: EXPERIMENTAL; Interventions: Other: Physician uniform | Intervention Type: OTHER; Name: Physician uniform; Assigned to Arm(s): Uniform group
B: Intervention Type: PROCEDURE; Name: Intensive Control Strategy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Standard Control Strategy; Assigned to Arm(s): N/A
C: Arm Label: Hand hygiene; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hand hygiene plus gloving; Type: EXPERIMENTAL; Interventions: Other: Gloves | Intervention Type: OTHER; Name: Gloves; Assigned to Arm(s): Hand hygiene plus gloving
D: Arm Label: Chromogenic Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Chromogenic surveillance | Arm Label: Molecular Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Molecular surveillance | Intervention Type: OTHER; Name: Chromogenic surveillance; Assigned to Arm(s): Chromogenic Arm | Intervention Type: OTHER; Name: Molecular surveillance; Assigned to Arm(s): Molecular Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
Brief Summary: The intake of high doses of corticosteroids is known to play an important role in the weakening of the bones and is thus an increasing fracture risk. Zoledronic acid (Aclasta) is a drug known for its protective effect in some bone diseases (tumors, paget). This study will test the safety and efficacy of zoledronic acid in the prevention and treatment of corticosteroid induced osteoporosis in male and female patients.


Options:
A: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M
C: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): Denosumab
D: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
Brief Summary: The intake of high doses of corticosteroids is known to play an important role in the weakening of the bones and is thus an increasing fracture risk. Zoledronic acid (Aclasta) is a drug known for its protective effect in some bone diseases (tumors, paget). This study will test the safety and efficacy of zoledronic acid in the prevention and treatment of corticosteroid induced osteoporosis in male and female patients.


Options:
A: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Biological: Denosumab | Intervention Type: BIOLOGICAL; Name: Denosumab; Assigned to Arm(s): Denosumab
B: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder
Brief Summary: The purposes of this study are to assess the efficacy, safety, and side effects among doses approved by the Food and Drug Administration and higher (not FDA approved) doses of olanzapine in patients with schizophrenia or schizoaffective disorder.


Options:
A: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
B: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder
Brief Summary: The purposes of this study are to assess the efficacy, safety, and side effects among doses approved by the Food and Drug Administration and higher (not FDA approved) doses of olanzapine in patients with schizophrenia or schizoaffective disorder.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone Palmitate | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Paliperidone Palmitate; Assigned to Arm(s): 001
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 1, 2, 3
C: Intervention Type: DRUG; Name: Intramuscular Olanzapine Depot; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Oral Olanzapine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%
Brief Summary: This study was not conducted in the United States. The purpose of this study was to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels in people with type 2 diabetes who had not previously been treated with drug therapy to lower their blood sugar and whose blood sugar levels were in a specified range.


Options:
A: Arm Label: Metformin,lifestyle counselling; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosiglitazone, Drug: metformin, Drug: Anti-diabetic medications | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): Metformin,lifestyle counselling | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Metformin,lifestyle counselling | Intervention Type: DRUG; Name: Anti-diabetic medications; Assigned to Arm(s): Metformin,lifestyle counselling
B: Intervention Type: DRUG; Name: Glucovance (metformin HCl/glyburide); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: or Metformin HCl alone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: or Glyburide alone.; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: D